Tratamiento del carcinoma broncogénico de célula no pequeña en estadios precoces. [artículo de revisión]
Por: Ávila Martínez, Régulo José [Cirugía Torácica]
| Bartolomé Villar, Adela [Oncología Radioterápica] | Meneses Pardo, José Carlos [Cirugía Torácica] | Gámez García, Pablo [Cirugía Torácica] | Ponce Aix, Santiago [Oncología Médica] | Zuluaga Bedoya, Mauricio [Cirugía Torácica].
Colaborador(es): Servicio de Oncología Médica | Servicio de Oncología Radioterápica | Servicio de Cirugía Torácica.
Editor: Cirugía española, 2013Descripción: 91(10):625-32.Recursos en línea: Solicitar documento Resumen: Treatment of lung carcinoma is multidisciplinary. There are different therapeutic strategies available, although surgery shows the best results in those patients with lung carcinoma in early stages. Other options such as stereotactic radiation therapy are relegated to patients with small tumors and poor cardiopulmonary reserve or to those who reject surgery. Adjuvant chemotherapy is not justified in patients with stage I of the disease and so double adjuvant chemotherapy should be considered. This adjuvant chemotherapy should be based on cisplatin after surgery in those patients with stages II and IIIA.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Revisión
|
PC14305 (Navegar estantería) | Disponible |
Formato Vancouver:
Meneses JC, Avila Martínez RJ, Ponce S, Zuluaga M, Bartolomé A, Gámez P. Tratamiento del carcinoma broncogénico de célula no pequeña en estadios precoces. Cir Esp. 2013 Dec;91(10):625-32.
PMID: 23829961
Contiene 49 referencias
Treatment of lung carcinoma is multidisciplinary. There are different therapeutic strategies available, although surgery shows the best results in those patients with lung carcinoma in early stages. Other options such as stereotactic radiation therapy are relegated to patients with small tumors and poor cardiopulmonary reserve or to those who reject surgery. Adjuvant chemotherapy is not justified in patients with stage I of the disease and so double adjuvant chemotherapy should be considered. This adjuvant chemotherapy should be based on cisplatin after surgery in those patients with stages II and IIIA.
No hay comentarios para este ejemplar.